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Abstract The concept of “pharmacogenomics” or “pharma-
cogenetics” promises to offer the ultimate in personalized
medicine, and the renin-angiotensin system (RAS) is one of
the most plausible candidates for the application of this
approach in the area of hypertension. For the past two
decades, genetic variants of the RAS have been tested for
association with blood pressure response, but the results have
been inconsistent. The problems have been attributed to many
issues, but the most fundamental concern is thought to be the
statistical power ofthe studies. Therefore, we have tried to put
together a new systematic review using a database search
including only recent reports with adequate numbers of
subjects, and 11 reports were identified. From the results, we
were able to draw conclusions with nearly consistent findings
that the conventional genetic variants of the system (i.e., the
ACE I/D, AGT M235T, AT1 A1166C, and AT2 variant) are
not associatedwithantihypertensiveeffects byRASblockade,
at least by one individual SNP. By contrast, significant
associations have been reported (by one report each) for
AGT rs7079, AT1 haplotype, REN, and ACE2. For these
variants, further evaluations and confirmation are anticipated.
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Introduction
Oneofthemostintriguingissuesforthenextstageofthepost-
genome era is “pharmacogenomics” or“pharmacogenetics,” a
concept that offers the ultimate personalized medicine, by
which favorable effects of medications are maximized and
adverse effects are minimized, compared with conventional
“trial and error” prescribing. This type of “tailored” medicine
is coming to be expected. In the area of hypertension, the
renin-angiotensin system (RAS) is the most plausible candi-
date for pharmacogenomics. The RAS plays major roles in
blood pressure regulation and electrolyte metabolism [1]a n d
also has pivotal roles in cardiovascular [2], renal [3], and
metabolic conditions [4]. During almost two decades, genetic
variants of this system have been tested for their association
with hypertension and cardiovascular conditions. Conven-
tionally (with controversy), angiotensin-converting enzyme
(ACE) insertion/deletion polymorphism has been associated
with ischemic heart disease [5] and the development of end-
stage renal diseases [6–9]. Angiotensinogen (AGT) M235T
has been associated with the development of hypertension
[10, 11]. Angiotensin II type 1 receptor (AT1) A1166C has
been associated with the development of hypertension and
ischemic heart disease [12, 13]. Recently, a number of large-
scale prospective studies have proven that RAS blockade has
favorable effects on cardiovascular and renal conditions [14–
19]. However, the association between genetic variants of the
RAS and the effects of angiotensin II receptor blockers
(ARBs) and ACE inhibitors was still unclear in a 2007
systematic review by Farahani et al. [20]. The uncertainty
has been attributed to many issues, but the most fundamental
concern is thought to be lack of statistical power. Therefore,
we have tried to produce an updated systematic review, using
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DOI 10.1007/s11906-011-0212-0a database search for the latest reports with adequate
numbers of subjects.
Identification of Studies
This review focuses on the genetic variants of the RAS and
blood pressure response to RAS blockade. Studies were
identified by an initial PubMed search with condition 1
((“pharmacogenetics”[All Fields] OR “pharmacogenomics”[All
Fields]) AND (“renin”[All Fields] OR “ACE”[All Fields] OR
“angiotensinogen”[All Fields])) or condition 2 ((“genetic
variant”[All Fields] OR “polymorphism”[All Fields]) AND
(“blood pressure response”[All Fields] OR (“blood pressure
responder”[All Fields]) AND “angiotensin”[All Fields]). Con-
dition 1 identified 136 studies, and condition 2 found 52. From
these studies (which included reviews), studies were identified
that evaluated the genes for ACE, AGT, AT1, angiotensin II
type 2 receptor (AT2), renin (REN), and angiotensin-converting
enzyme 2 (ACE2). The evaluated RAS-blocking drugs were
ARBs and ACE inhibitors.
Practical clinical implications require detection of a
difference in diastolic blood pressure between groups of
almost 5 mm Hg. Thus, we calculated the necessary sample
size of the study, assuming a standard deviation for the
diastolic blood pressure of 10 mm Hg by a bilateral paired
Student’s t-test with protection against type I error of 5%
and 80% of power, and determined that a study required
200 subjects in total to have adequate statistical power. We
therefore adopted studies with about 200 or more subjects
for assessment, finding the 11 studies shown in Table 1.
Three of these studies tested ARBs and eight looked at
ACE inhibitors.
ACE Gene Variant
The most evaluated gene in pharmacogenomics studies for
the RAS is ACE, especially the insertion and deletion (I/D)
genetic variant of intron 16. The first report, from Rigat et
al. [21], indicated that serum ACE concentration differs
according to the I/D allele numbers, and this phenomenon
has been reconfirmed in many studies. Accordingly, the I/D
variant is one of the most plausible candidates for
pharmacogenomic RAS blockade intervention. Indeed,
early studies showed significant differences of blood
pressure reduction among the variants. A greater reduction
by enalaprilat in II genotype compared with DD genotype
was reported in 23 normotensive men [22], and a greater
reduction by irbesartan in D allele compared with I allele
was reported in 43 hypertensive patients [23]. However, as
shown in Table 1, recent relatively well-powered studies
have almost consistently shown no difference in blood
pressure reduction in ACE genotypes (mainly the I/D
variant) by ARBs [24￿￿, 25￿￿, 26] or ACE inhibitors [27–
29]. Thus, we may conclude that the ACE I/D gene variant
is not associated with antihypertensive effects from RAS
blockade.
AGT Gene Variant
Another of the most evaluated genes in pharmacogenomics
studies for the RAS is AGT, especially the M235T genetic
variant. Evidence of genetic linkage between the AGT gene
and hypertension, as well as association of AGT with the
disease, has been observed, and significant differences in
plasma concentrations of angiotensinogen were found among
hypertensive subjects with different AGT genotypes [10].
Thus, the AGT variant is one of the most plausible candidates
for pharmacogenomic RAS blockade intervention. Although
one previous study of 125 cases reported that M235T was
associated with lowered blood pressure in response to ACE
inhibitors [30], the recent relatively well-powered studies in
Table 1 almost consistently observed no difference in blood
pressure reduction with M235T and A-6G (which is thought
to be in linkage disequilibrium with M235T) by ARBs [24￿￿,
25￿￿, 26] or ACE inhibitors [27, 31]. Thus, it seems that we
can conclude that the conventional AGT gene variant,
M235T, is not associated with antihypertensive effects of
RAS blockade.
Su et al. have reported that M235T is not associated with
the antihypertensive effects of benazepril, but a new single
nucleotide polymorphism (SNP), rs7079 (C11537A), is
associated with blood pressure reduction in response to
benazepril [32]. As this is the only report regarding rs7079
(C11537A) of AGT, further evaluations are expected.
AT1 Gene Variant
The AT1 genetic variant, especially A1166C, also has been
widely evaluated as a candidate for pharmacogenomic
study for the RAS. This variant originally was associated
with hypertension and ischemic heart disease [12, 13].
Unlike ACE and AGT, it has no evident intermediate
phenotype, such as blood concentrations, but the AT1
variant is nevertheless one of the most plausible pharma-
cogenomic candidates for RAS blockade intervention, as a
major component of the system. As shown in the Table 1,
recent relatively well-powered studies have consistently
found no difference for A1166C in blood pressure
reduction by ARBs [24￿￿, 25￿￿, 26] and ACE inhibitors
[27, 33, 34]. Thus, we may conclude that the conventional
AT1 gene variant, A1166C, is not associated with the
antihypertensive effects of RAS blockade.
Curr Hypertens Rep (2011) 13:356–361 357Again, however, Su et al. reported that individual SNPs
including A1166C are not associated with the antihyper-
tensive effects of benazepril but two haplotypes of AT1
(H2, H3) are associated with blood pressure reduction in
response to benazepril [32]. As this is the only report
regarding the haplotypes of AT1, further evaluations are
expected.
AT2 Gene Variant
AT2, a subtype of the angiotensin II receptor, which is
thought to be expressed considerably less in adult tissues
than AT1, functions as a vasodilator and has some
antiproliferative effects against the AT1 receptor. From
database research, we identified two studies about AT2:
one is ours, using an ARB [25￿￿], and the other is
haplotype analysis with an ACE inhibitor [32]. As the AT2
gene is located on the X chromosome, the evaluation is a
little complicated. In our study, we grouped the genotype
by the presence or the absence of the A allele, and the
other study evaluated haplotypes separately for males and
females. No significant difference in blood pressure
reduction was observed in these two studies. As these
are the only two reports regarding AT2, further evaluations
are expected.
Table 1 Pharmacogenomics in the renin-angiotensin system (RAS): Studies of blood pressure response to RAS blockade among genetic variants
Study Year Area Ethnicity Patients,
N
Drug
class
Drug Genetic variant of
the RAS
Significant
difference?
Nordestgaard et
al. [24￿￿]
2010 Scandinavia White
(92%)
1,774 ARB Losartan ACE (I/D) No
AGT (M235T) No
AT1 (A1166C) No
Konoshita et al.
[25￿￿]
2009 Japan Japanese
(100%)
231 ARB Valsartan ACE (I/D) No
AGT (M235T) No
AT1 (A1166C) No
AT2 (C3123A) No
REN (C-5312T) Yes
Redon et al. [26] 2005 Spain Spanish
(100%)?
206 ARB Telmisartan ACE (I/D) No
AGT (A-6G) No
AT1 (A1166C, No
C573T) No
Yu et al. [33] 2009 China Chinese
(100%)
509 ACEI Imidapril or
benazepril
AT1 (A1166C) No
Filigheddu et al.
[27]
2008 Italy (North
Sardinia)
White
(100%)
191 ACEI Fosinopril ACE (I/D) No
AGT (A-6G) No
AT1 (A1166C) No
Fan et al. [43] 2007 China Chinese
(100%)
624 ACEI Captopril ACE2 (rs2106809) Yes
Brunner et al.
[34]
2007 USA White
(35%)
551 ACEI Trandolapril AT1 (A1166C) No
Hispanic
(44%)
Su et al. [32] 2007 China
(Shanghai)
Chinese
(100%)
1,447 ACEI Benazepril AGT (multi loci) Yes
AT1 (multi loci) Yes
AT2 (multi loci) No
Arnett et al. [28] 2005 USA White
(61%)
7,528 ACEI Lisinopril ACE (I/D) No
Black
(35%)
Yu et al. [31] 2005 China Chinese
(100%)
501 ACEI Imidapril or
benazepril
AGT (M235T) No
Yu et al. [29] 2003 China Chinese
(100%)
517 ACEI Imidapril or
benazepril
ACE (I/D) No
ARB angiotensin receptor blocker; ACE angiotensin-converting enzyme, ACEI ACE inhibitor; ACE (I/D) insertion and deletion genetic variant of
intron 16; AGT angiotensinogen; AT1 angiotensin II type 1 receptor; AT2 angiotensin II type 2 receptor; REN renin
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In the whole body of the RAS, renin is the first step and the
rate-limiting enzyme. The gene is supposed to play a major
role in blood pressure regulation and in the response to RAS
blockade interventions. However, REN has not been exam-
inedasacandidateforpharmacogenomics.Toourknowledge,
our study [25￿￿] is the only one to report on the relationship
between the genetic variants and blood pressure effects of
RAS blockade with an adequate sample size. This study
comprised 231 hypertensive patients, who were given 40 to
160 mg per day of valsartan as monotherapy for 3 months.
Changes in diastolic blood pressure differed significantly
between genotypes of REN C-5312T: the reduction was
10.7 mm Hg (from 95.9±12.9 to 85.2±11.4) in CC versus
7.0 mm Hg reduction (from 94.7±14.0 to 87.7±12.6) in CT/
TT (P=0.02 for interactive effects of valsartan and geno-
type). Responder rates also differed between the genotypes:
72.8% in CC versus 58.0% in CT/TT (P=0.03). Multiple
logistic regression analysis revealed that CC homozygotes of
REN C-5312T were an independent predictor for response,
with an odds ratio of 2.03 (95% CI, 1.10–3.74).
A plausible explanation is as follows: As shown in
Fig. 1, our recent studies of the transcription mechanism of
the human renin gene revealed that multiple trans-factors
and cis-elements are involved in the transcriptional regula-
tion [35–39]. A distal enhancer, a 225-bp region located
−5,777/−5,552 base upstream of the human renin gene,
gave about 57-fold higher transcription rates [38]. REN C-
5312T of the human renin gene was discovered as a
functional new polymorphism in this distal enhancer region
[40]. The levels of transcription were 45% greater with the
5312T variant than with the 5312C variant. Thus, the
variant was validated as a functional SNP. The results of the
study demonstrated that the homozygote of the C allele
shows greater blood pressure reduction from ARBs than the
T allele carrier and can be a predictor of response. One
explanation may be that homozygotes of the C allele may
have a lower level of tissue renin concentration and are
more affected by the drug than T allele carriers. As this is
the only report regarding REN, further evaluations are
expected, especially to explore the RAS blockade response
with different therapeutic combinations. The distinct effects
on the RAS by target channel subtype, as shown for
calcium channel blockers [41￿], should be well considered.
ACE2 Gene Variant
ACE2, a newly emerging component of the renin-
angiotensin system (RAS), is presumed to be a counter-
regulator against ACE in degrading angiotensin II to
angiotensin 1–7, which is thought to act as a vasodilator
and to be involved in apoptosis and growth arrest [42].
Accordingly, ACE2 is also a plausible candidate for
pharmacogenomic study for the RAS. To our knowledge,
only the study by Fan et al. [43] has yet reported a
relationship between genetic variants of ACE2 and blood
pressure effects with RAS blockade. These authors reported
that the adjusted diastolic blood pressure response to
captopril in women was 3.3 mm Hg lower in ACE2
rs2106809 T allele carriers than in CC genotype carriers (P=
0.019). As this is the only report regarding ACE2, further
evaluations are expected.
Conclusions
A previous well-documented review of this issue in 2007 [20]
identified no consistent conclusions, but problems have been
attributed to methodologic limitations such as race, patient
selection, behavioral factors such as salt intake, combining of
different therapies, drug dose, administration term and drug
selection, statistical power, combining of different alleles,
and end points such as definition of responders. We thought
that one of the most important and fundamental concerns
should be statistical power estimation. Considering practical
clinical implications, the significant and adequate difference
Fig. 1 Structure of transcriptional regulatory elements for the human
renin gene. The horizontal bars represent alignment of the gene, and
the vertical bars represent exons. Shown are a the proximal promoter;
b the negative calcium response element (nCaRE); c the distal
enhancer; d the tissue-specific expression-determining element; a Ets
motif; b HOX-PBX motif; c no known consensus; d cAMP response
element (CRE); e direct repeat (DR) motif; f AGE3-like site. (From
Konoshita et al. [37], with permission of John Wiley and Sons.)
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Thus, the needed minimum sample size was calculated to be
about 200 subjects in total. By selecting studies with about
200 or more subjects, we tried to produce an updated
statistical review, and we obtained relatively consistent
results, concluding that the conventional genetic variants of
the system—the ACE I/D, AGT M235T, AT1 A1166C, and
AT2 variant—are not associated with the antihypertensive
effects of RAS blockade, at least by individual SNPs. In
contrast, significant associations have been reported with
AGT rs7079, AT1 haplotype, REN, and ACE2, each in one
report. For these variants, further evaluations are expected.
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